Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07191951

Shanghai Clinical Cohort - Adrenal Disease

As a vital organ responsible for producing life-sustaining hormones, the adrenal gland is associated with a wide range of diseases. These diseases affect multiple systems throughout the body and carry a high rate of mortality and disability. Current diagnosis and treatment face several challenges: significant variability in hormone testing results, inaccurate localization via imaging techniques, unclear molecular characteristics of adrenal tumors, and difficulty in determining prognosis through pathology. Therefore, establishing a clinical research cohort for adrenal diseases is essential. Such a cohort will enable in-depth exploration of disease mechanisms, identification of disease subtypes, optimization of diagnostic criteria, evaluation of treatment efficacy, advancement of personalized medicine, and formulation of prevention and treatment strategies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Adrenal Disease Adrenal Gland Diseases Endocrine System Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A signed and dated informed consent form
  • Commitment to abide by the study procedures and cooperate with the implementation of the entire study process
  • Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy
  • Aged between 18 and 75 years

Exclusion criteria

  • Subjects meeting any of the following criteria will be excluded from this study:
  • Refuse to sign the informed consent form
  • Patients without adrenal diseases
  • Have specified diseases or conditions (physical or psychological, identified through physical examination) that warrant exclusion from the study

Treatment and study plan

Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.

Other

Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.

Primary outcomes

  1. Post-Treatment Remission Rate

    Time frame: at least six months or more

  2. Treatment Response Rate

    Time frame: at least six months or more

Study contacts

Contact information is provided by the study sponsor or research team.

Yiran Jiang

CONTACT

[email protected]

0086-021-64370045

Sponsors and collaborators

Lead sponsor

Shanghai Jiao Tong University School of Medicine

Other

Collaborators

  • RenJi Hospital
  • Ruijin Hospital
  • Shanghai Public Health Clinical Center
  • Shanghai Zhongshan Hospital

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Sep 25, 2025
Registry last updated
Nov 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.